Last reviewed · How we verify
Randomized Controlled Trial of S-1 Maintenance Therapy in Metastatic Esophagogastric Cancer (MATEO)
The aim is to assess the relative efficacy of S-1 de-escalation therapy vs. continuation of chemotherapy after induction therapy in patients with metastatic esophagogastric cancer in terms of overall survival.
Details
| Lead sponsor | AIO-Studien-gGmbH |
|---|---|
| Phase | Phase 2 |
| Status | COMPLETED |
| Enrolment | 242 |
| Start date | 2014-09 |
| Completion | 2020-10-08 |
Conditions
- Unresectable, Locally Advanced or Metastatic, Adenocarcinoma of the Stomach, or of the Gastro Esophageal Junction
- Gastric Neoplasm
- Gastroesophageal Junction Adenocarcinoma
- Esophageal Adenocarcinoma
- Gastric Adenocarcinoma
- Esophageal Neoplasms
Interventions
- S-1 de-escalation
- Chemotherapy by Investigator's choice
Primary outcomes
- Overall Survival (OS) — approx. 12 month
OS will be defined as the time length between randomization and the date of death from any cause or the date of last follow-up in case of no documentation of death.
Countries
Germany